LAVA Therapeutics NV
LVTX
Market Cap$41.3M
Close$
$-2.51
262.2% downside
Current Fair Value
262.2% downsideOvervalued by 262.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $41.30 Million |
|---|---|
| Enterprise Value | $15.22 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.94 |
| Beta | 0.49 |
| Outstanding Shares | 26,899,122 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.49 |
|---|---|
| PEG | -35.99 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 3.05 |
| Enterprise Value to EBIT | -0.67 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About LAVA Therapeutics NV
LAVA Therapeutics N.V. is a biotechnology company developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its proprietary platform. The...